October 05, 2021
Comparison of Rheumatoid Arthritis Patients Recently Switched to JAK Inhibitor Therapy in the US and EU5: Comorbidity and Switch Pattern Analysis from Patient Chart Audit
Authors: Maxine Yarnall, Chrystal Ferguson
BACKGROUND and AIMS:
As use of Januse Kinase Inhibitor (JAKi) therapies in rheumatoid arthritis (RA) have increased, so has awareness of cardiovascular (CV) and malignancy safety concerns associated with the class. This study’s goal is to compare gender, comorbidities and JAKi use in RA patients switched to JAKi therapies in the US and EU5.
In July-September 2020, US (n=200) and EU5 (n=310) rheumatologists contributed patient chart data for biologic/JAK treated RA patients (US (n=1,000); EU5 (n=1,288)). Data has been collected annually in the US since 2016 and EU5, 2017.
US females switched to a JAKi therapy were statistically more likely to have a high CV risk and obesity compared to EU5 females (figures 1a &1b). EU5 males were statistically more likely to have malignancy risk and a history of smoking than US males (figures 2a & 2b). Additionally, statistical differences were found between the genders within a region. Tofacitinib use is higher than baricitinib in the US, while the opposite in the EU5 (figure 3). JAK cycling has increased in both regions year over year (figure 4).
Different considerations between genders and regions should be given when switching RA patients to JAKi therapy in the US and EU5.
MY, CF: Spherix Global Insights, Exton, PA, USA
Archived LUPUS & CORA Abstracts: